unknown
Stage
1
Investors
About
Cytoki Pharma is a biotechnology company developing protein therapeutics for diseases characterized by epithelial injury, with a focus on a licensed long-acting IL-22 program for inflammatory bowel disease. The company also has a clinical program (CK-0045) in Phase 2 for obesity and type 2 diabetes.
Explore Cytoki Pharma's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.